JUL 26, 2016 5:40 AM PDT

Certain Colon Cancer Can be 'Starved' to Death

WRITTEN BY: Xuan Pham

Colon cancer is the third most common non-skin cancer type in the U.S. Now researchers say they have gained a huge advantage in discovering the key compound that sustains a large portion of these cancers. By blocking the compound, researchers showed significant tumor reduction. The findings are so promising that clinical trials for colorectal cancer patients will be starting this August at the University Hospitals Seidman Cancer Center.
 


Approximately over 1 million Americans are diagnosed with colorectal cancer, also known as colon cancer. Of these cases, about a third are due to mutations in a gene known as PIK3CA, which is involved in critical cell signaling processes such as cell growth and division, migration, and survival. Mutations in this gene are also responsible for a host of other cancer types, including lung cancer, breast and ovarian cancer, and head and neck cancer.

In studying colon cancer cells with PIK3CA mutations, the team at Case Western Reserve noted a very specific pattern of metabolism. In particular, they found that cells with PIK3CA mutations broke down the amino acid glutamine at a significantly faster pace than cells without the mutation. The increased need for glutamine stemmed from cancer cells’ overactive enzyme activities. Thus, glutamine is necessary in the colon cancer cells’ survival.

“We discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs," said Zhenghe John Wang, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University, and senior author of the study.
 

Image credit: Pixabay.com

Indeed, when the team starved mutant cells of glutamine, they observed more cell death. Even more promising, when they reduced glutamine levels in mice with colon cancer, they saw slower and smaller tumor growths. The same treatment in cancer cells without the PIK3CA mutation were not effective, indicating a specific link between PIK3CA and glutamine.

Glutamine is a non-essential (or conditional) amino acid that can be made by the body under the appropriate conditions. Its levels can be easily modulated with glutamine blockers, making treatment relatively straightforward. Furthermore, because PIK3CA is a well-known player in many other types of cancer makes the results are broadly appealing. As such, Phase I/II clinical trials stemming from this study are already planned for this later this summer.

"This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center," according to Neal Meropol, chief of the division of hematology and oncology, and lead investigator for the trial.

Additional source: Case Western Reserve University materials via EurekAlert!

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 19, 2022
Cancer
Developing Methods to Predict Breast Cancer Recurrence
MAY 19, 2022
Developing Methods to Predict Breast Cancer Recurrence
Recurrent cancer develops when undetectable cancer cells remain in the body following treatment.  Cancer recurrence ...
JUN 26, 2022
Drug Discovery & Development
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
JUN 26, 2022
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
The US Preventive Services Task Force (USPSTF) recommends against using beta carotene or vitamin E supplements to preven ...
JUN 29, 2022
Clinical & Molecular DX
New Study Shows Higher Risk of Cardiovascular Disease in Adult Cancer Survivors
JUN 29, 2022
New Study Shows Higher Risk of Cardiovascular Disease in Adult Cancer Survivors
With modern diagnostics and treatments, cancer survival rates continue to improve. Though numbers vary depending on the ...
JUL 25, 2022
Cancer
Does the Secret to Immunotherapy Lie in...Poop?
JUL 25, 2022
Does the Secret to Immunotherapy Lie in...Poop?
Advancements in immunotherapy have proven instrumental in reshaping the face of cancer research in recent years.  W ...
AUG 29, 2022
Cancer
Could Robotic Surgery Provide Better Care for Patients with Kidney Cancer?
AUG 29, 2022
Could Robotic Surgery Provide Better Care for Patients with Kidney Cancer?
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for about 90% of kidney cancer incidence ...
SEP 11, 2022
Microbiology
Using Yeast Cells to Make a Cancer Treatment
SEP 11, 2022
Using Yeast Cells to Make a Cancer Treatment
Vinblastine and vincristine are both common chemotherapies that are used to treat several types of cancer. The drugs sto ...
Loading Comments...